Publication:
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

Simple item page
dc.contributor.authorCobo-Vuilleumier, Nadia
dc.contributor.authorLorenzo, Petra I.
dc.contributor.authorGarcía Rodríguez, Noelia
dc.contributor.authorHerrera Gómez, Irene de Gracia
dc.contributor.authorFuente-Martin, Esther
dc.contributor.authorLópez-Noriega, Livia
dc.contributor.authorMellado-Gil, José Manuel
dc.contributor.authorRomero-Zerbo, Silvana-Yanina
dc.contributor.authorBaquié, Mathurin
dc.contributor.authorLachaud, Christian Claude
dc.contributor.authorStifter, Katja
dc.contributor.authorGerman, Perdomo
dc.contributor.authorMarco, Bugliani
dc.contributor.authorDe Tata, Vincenzo
dc.contributor.authorBosco, Domenico
dc.contributor.authorParnaud, Geraldine
dc.contributor.authorPozo, David
dc.contributor.authorHmadcha, Abdelkrim
dc.contributor.authorFlorido, Javier P.
dc.contributor.authorToscano, Miguel G.
dc.contributor.authorde Haan, Peter
dc.contributor.authorSchoonjans, Kristina
dc.contributor.authorSánchez Palazón, Luis
dc.contributor.authorMarchetti, Piero
dc.contributor.authorSchirmbeck, Reinhold
dc.contributor.authorMartín-Montalvo, Alejandro
dc.contributor.authorMeda, Paolo
dc.contributor.authorSoria, Bernat
dc.contributor.authorBermúdez-Silva, Francisco-Javier
dc.contributor.authorSt-Onge, Luc
dc.contributor.authorGauthier, Benoit R.
dc.contributor.authoraffiliation[Cobo-Vuilleumier,N; Lorenzo,PI; García Rodríguez,N; Herrera Gómez,IG; Fuente-Martin,E; López-Noriega,L; Mellado-Gil,JM; Claude Lachaud,C; Hmadcha,A; Martín-Montalvo,A; Soria,B; Gauthier, BR] Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC, Seville, 41092, Spain. [Romero-Zerbo,SY; Bermúdez-Silva,FJ] Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, 29010, Spain. [Romero-Zerbo,SY; Hmadcha,A; Soria,B; Bermúdez-Silva,FJ] Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, 28029, Spain. [Baquié,M] Neurix SA, Geneva, 1228, Switzerland. [Stifter,K; Schirmbeck,R] Ulm University Hospital, Ulm, 89081, Germany. [Perdomo,G] Facultad de Ciencias de la Salud, Universidad de Burgos, Burgos, 09001, Spain. [Bugliani,M; Marchetti,P] Department Clinical and Experimental Medicine, University of Pisa—AOUP University Hospital, Pisa, 56126, Italy. [De Tata,V] Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, 56126, Italy. [Bosco,D; Parnaud,G] Cell Isolation and Transplantation Centre, University Hospital, Geneva, 1211, Switzerland. [Pozo,D] Department of Cell Dynamics and Signalling, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine, Seville, 41092, Spain. [Florido,JP] Clinical Bioinformatics Area, Fundación Progreso y Salud, Consejería de Salud, Seville, 41013, Spain. [Toscano,MG; de Haan,P] Amarna Therapeutics, Seville, 41092, Spain. [Schoonjans,K] Laboratory of Metabolic Signaling, EPFL, Lausanne, 1015, Switzerland. [Sánchez Palazón,L] Biological Resources, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine, Seville, 41092, Spain. [Meda,P] Department of Cell Physiology and Metabolism, University of Geneva, Geneva, 1211, Switzerland. [St-Onge,L] Neuried Munich, 82061, Germany.
dc.date.accessioned2024-02-08T14:41:14Z
dc.date.available2024-02-08T14:41:14Z
dc.date.issued2018-04-16
dc.description.abstractType 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus.
dc.identifier.doi10.1038/s41467-018-03943-0
dc.identifier.e-issn2041-1723es_ES
dc.identifier.journalNature Communicationses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/2858
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17588
dc.language.isoeng
dc.publisherSpringer
dc.relation.publisherversionhttps://www.nature.com/articles/s41467-018-03943-0es
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectIslets of Langerhans
dc.subjectType 1 diabetes
dc.subjectType 2 diabetes
dc.subjectIslotes Pancreáticos
dc.subjectDiabetes Mellitus Tipo 1
dc.subjectDiabetes Mellitus Tipo 2
dc.subjectDiabetes Mellitus
dc.subjectDiabetes
dc.subject.meshDiabetes Mellitus, Type 1
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshIslets of Langerhans
dc.subject.meshDiabetes Mellitus
dc.subject.meshMurinae
dc.subject.meshAnimals
dc.titleLRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication8d558850-2ef2-4d1e-b0e1-4e5591ab6288
relation.isPublisherOfPublication.latestForDiscovery8d558850-2ef2-4d1e-b0e1-4e5591ab6288

Files

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)